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As they mentioned, one study by Chan et al. [1] was not included in our systematic review. Chan et al. focused on the effect of dexamethasone on the reoperation rate rather than the recurrence. It was reported that cSDH patients with recurrent haematoma would be effectively treated with dexamethasone treatment once again avoiding reoperation [2] . So the reoperation rate and recurrence rate were not in full accord. In this point, we tried to distinguish the reoperation and recurrence but found it difficult because of few studies referring to their difference. Moreover, after adding Chan's study to the metaanalysis, the overall effect (RR, 0.52; 95% CI, 0.34-0.80; p = 0.003) was statistically consistent with our result (RR, 0.54; 95% CI, 0.33-0.88; p = 0.01).
The change of cSDH is a dynamic process influenced by multiple factors. We agree with that coagulation dysfunction plays an important role in the extension of cSDH. Although the osmotic and oncotic theories are questioned by some researchers, further study is needed before totally denying their effects on the cSDH. In addition, as mentioned by Turgut, bridging veins passing through the dural border cell layer may be the potential source of rebleeding.
The spontaneous regression and resolution of cSDH are rarely encountered. Our result also showed treatment with dexamethasone alone did not result in a better outcome. However, adjuvant dexamethasone exhibited an advantage to facilitate surgical treatment and reduce recurrence. In future studies, the adjuvant effect of dexamethasone should be the focus.
